ACP
FENC icon

Acuta Capital Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Acuta Capital Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-250,000
Closed -$2.61M – 37
2018
Q2 		$2.61M Hold
250,000
– – 0.46% 34
2018
Q1 		$3.02M Hold
250,000
– – 0.49% 28
2017
Q4 		$2.5M Hold
250,000
– – 0.47% 30
2017
Q3 		$2.77M Buy
+250,000
New +$2.9M 0.5% 34

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acuta Capital Partners's FENC Position: Q3 2018 in Review

Acuta Capital Partners sold out of Fennec Pharmaceuticals (FENC) in Q3 2018, closing a stake of 250,000 shares — an estimated $2.61M sold.

Acuta Capital Partners first reported a position in FENC in Q3 2017 and held it in 4 quarters. The position peaked at $3.02M in Q1 2018. 48 funds tracked by Wall St. Rank hold FENC as of Q3 2018.

  • Acuta Capital Partners reported no remaining Fennec Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 250,000 Fennec Pharmaceuticals shares in Q3 2018, an estimated $2.61M.
  • Acuta Capital Partners first reported a position in Fennec Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Acuta Capital Partners's Fennec Pharmaceuticals position peaked at $3.02M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2018.

Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.